{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-002314","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.107389+00:00","generated_at":"2026-06-25T03:31:10.537960+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Chemomab reports 2022 Annual Meeting vote results; all proposals pass","bullets":["Proposal 1: re-elect Dr. Nissim Darvish as Class I director received 84,055,680 FOR, 591,060 AGAINST.","Proposal 2: approve amendment to compensation of Dr. Adi Mor (CSO) passed with 83,840,260 FOR.","Proposal 4: reappoint Somekh Chaikin (KPMG) as auditor approved with 84,152,640 FOR.","Proposal 3 (equity grants to directors) was withdrawn prior to the meeting.","Total shares represented: 84,756,220 ordinary (37.16% of outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-002314","json":"https://secwatch.observer/filing/0001178913-22-002314.json","markdown":"https://secwatch.observer/filing/0001178913-22-002314.md","text":"https://secwatch.observer/filing/0001178913-22-002314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322002314/0001178913-22-002314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322002314/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:31:10.537960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}